GlassScriptPhysician profile
Raymond S Bianchi
NPI 1114916558
$27,455.38
in general payments reported to CMS, 2019-2025
53 companies · $3,734 in 2025
The $3,734 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,865 · 2020: $4,065 · 2021: $4,500 · 2022: $3,116 · 2023: $2,114 · 2024: $3,061 · 2025: $3,734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,909.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $4,172.44 | 2019-2024 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $3,693.62 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $2,630.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,299.80 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $1,798.29 | 2019-2025 | Spravato, Xarelto |
| Lilly USA, LLC | $1,589.94 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $1,509.05 | 2019-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $1,504.79 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $1,289.85 | 2021-2025 | Vraylar, Ubrelvy, Viberzi |
| Pfizer INC. | $1,060.72 | 2019-2025 | |
| Amarin Pharma, INC. | $601.27 | 2019-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $389.00 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $368.72 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $340.36 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $315.57 | 2019-2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Bianchi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.